OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma

Reuters

2025/10/10

<a href="https://laohu8.com/S/OSTX">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma

OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p < 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2574112473"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574112473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574112473?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574112473","market":"us","top_or_hot":-1,"title":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p &lt; 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-10 18:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p &lt; 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5jKSG5:1","article_id":"2574112473","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574112473","pubTimestamp":1760090468,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients  achieved 2-year overall survival, compared with 40% in historical controls . Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival  reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSTX":"OS Therapies"},"translate_title":"OS Therapies宣布OSTHER2治疗转移性骨肉瘤的积极2b期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9},"content_text":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma\n    \n\n        OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients (27 out of 36 evaluable patients) achieved 2-year overall survival, compared with 40% in historical controls (p < 0.0001). Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival (EFS) reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 269942) on October 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}